Author

Bernadetta Majorek‐Olechowska

Observed names: B Majorek-Olechowska, B. Majorek-Olechowska, Bernadetta Majorek-Olechowska

Observed institution: Faes Farma (Spain)

OpenAlex ID: A5023558352

Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial

2018 · William W Busse, Eugene R Bleecker, et al. · The Lancet Respiratory Medicine · 328

Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis

2023 · Eric L. Simpson, Melinda Gooderham, et al. · JAMA Dermatology · 163

Efficacy and safety of bilastine in reducing pruritus in patients with chronic spontaneous urticaria and other skin diseases: an exploratory study

2019 · Esther Serra, Cristina Campo, et al. · Journal of Dermatological Treatment · 25

A phase 2a proof of concept clinical trial to evaluate ZPL-3893787 (ZPL-389) a potent, oral histamine H4, receptor antagonist for the treatment of moderate to severe atopic dermatitis (AD) in adults

2016 · Thomas Werfel, Victoria Lynch, et al. · ORBi (University of Liège) · 15

Pharmacokinetics and Safety of Bilastine 10 mg/d in Children Aged 2 to 5 Years With Allergic Rhinoconjunctivitis or Urticaria: A Phase 3 Clinical Trial

2024 · B Majorek-Olechowska, T Slomskis, et al. · Journal of Investigational Allergology and Clinical Immunology · 6

A new formulation of fluticasone propionate/salmeterol in a metered-dose inhaler (MDI HFA) allows for the reduction of a daily dose of corticosteroid and provides optimal asthma control - A randomized, multi-center, non-inferiority, phase IV clinical study

2020 · Maciej Kupczyk, Paweł Majak, et al. · Respiratory Medicine · 6

Rezpegaldesleukin treatment of moderate-to-severe atopic dermatitis (REZOLVE-AD): final results from the 16-week induction period of an international, double-blind, placebo-controlled, randomised phase 2b study

2026 · Jonathan I Silverberg, David Rosmarin, et al. · The Lancet · 5

Once-daily fluticasone furoate/vilanterol vs once-daily fluticasone furoate in patients with asthma aged 5 to 17 years

2024 · Philippe Bareille, Richard Forth, et al. · Annals of Allergy Asthma & Immunology · 3

A multicenter randomized, double‐blind, placebo‐controlled, parallel‐group study to evaluate the effects of a 1‐year regimen of orally inhaled fluticasone furoate 50 µg once daily on growth velocity in prepubertal, pediatric participants with well‐controlled asthma

2023 · Philippe Bareille, Varsha Imber, et al. · Pediatric Pulmonology · 3

Safety, Tolerability and Efficacy of Cat-Peptide Antigen Desensitisation (Cat-PAD) in Cat-Allergic Children – Findings from a Pilot Study

2017 · Stephen Pawsey, Rod P. Hafner, et al. · Journal of Allergy and Clinical Immunology · 3

A Randomised, Double-Blind, Parallel Group, Multicentre, Stratified Study Evaluating the Efficacy and Safety of Once-Daily Fluticasone Furoate/Vilanterol Compared With Once-Daily Fluticasone Furoate in the Treatment of Asthma in Participants Aged 5-17 Years Old Currently Uncontrolled on Inhaled Corticosteroids (ICS)

2023 · P. Bareille, R. Forth, et al. · American Journal of Respiratory and Critical Care Medicine

Efficacy and safety of new formulation of fluticasone propionate/salmeterol delivered via a HFA pMDI inhaler in patients with asthma

2020 · Maciej Kupczyk, Pawel Majak, et al. · European Respiratory Journal

[Measurement of the passive compliance of the total respiratory system in newborn after respiratory insufficiency for risk assessment of respiratory disorders during the first 6 month of life].

2010 · Wiesław Olechowski, Bernadetta Majorek-Olechowska · PubMed

Works count: 13

Citation count: 557

H-index: 6

I10-index: 4